In January 2005, Siskinds filed a class proceedings against Pfizer Canada Inc. and Pfizer Inc. with respect to Neurontin. Neurontin (generic name is "gabapentin") is a prescription anticonvulsant medication approved for use as a therapeutic antiepileptic agent, specifically as an adjunctive therapy for seizures. The vast majority of Neurontin sales are prescribed for "off label" use and ingestion of Neurontin has been linked to an increased risk of suicidal behaviour.

A settlement was achieved, which resolves the litigation in its entirety. The claims deadline has now passed (December 16, 2013). The settlement has concluded and all approved claims have been paid.